Vapotherm logo
Vapotherm VAPO
report update icon

Quarterly report 2024-Q2
added 05-23-2026

Vapotherm Balance Sheet 2023-2011 | VAPO

Brief overview of Vapotherm's balance sheet strength

The review uses the five latest available annual reports between 2019 and 2023.

Assets finished at $77.6 million versus $111.9 million initially, losing -30.6%. The balance sheet contracted.

Asset growth of -30.6% came with a +128.6% rise in liabilities. Financial leverage became more prominent.

The period ended with negative equity, a structure associated with elevated financial vulnerability.

The balance sheet holds more cash than interest-bearing debt; net debt is -$4.4 million, indicating minimal leverage.

The cash reserve occupies 12.5% of the balance sheet, previously 64%. It is one marker of short-term resilience.

The balance sheet includes a negative accumulated result of -$548.2 million. It should be assessed alongside historical profits and capital distributions.

Balance sheet takeaway

Vapotherm has limited balance sheet resilience and depends heavily on cash generation and refinancing capacity.

Annual Balance Sheet Vapotherm

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-4.39 M -7.54 M -50 M -105 M -29.9 M -26.9 M -4.56 M 6.11 M - - - - -

Long Term Debt

2.92 M 5.88 M 5.36 M 6.78 M 41.8 M 31.3 M 18.9 M 9.46 M - - - - -

Long Term Debt Current

2.41 M 2.31 M 1.75 M 1.57 M - - - - - - - - -

Total Non Current Liabilities

- - - 15.2 M 42 M 31.6 M 172 M 118 M - - - - -

Total Current Liabilities

19.1 M 19.6 M 43.2 M 42 M 16.2 M 14 M - - - - - - -

Total Liabilities

133 M 124 M 93.4 M 102 M 58.2 M 45.7 M 187 M 127 M - - - - -

Deferred Revenue

1.04 M 1.02 M 1.71 M 2.52 M 344 K 251 K 64 K 63 K - - - - -

Retained Earnings

-548 M -490 M -377 M -317 M -265 M -214 M -172 M -141 M - - - - -

Total Assets

77.6 M 96.2 M 160 M 216 M 112 M 97.2 M 60.2 M 30.9 M - - - - -

Cash and Cash Equivalents

9.72 M 15.7 M 57.1 M 114 M 71.7 M 58.2 M - - - - - - -

Book Value

-55.3 M -28.2 M 66.7 M 114 M 53.7 M 51.6 M -127 M -96.3 M - - - - -

Total Shareholders Equity

-55.3 M -28.2 M 66.7 M 114 M 53.7 M 51.6 M - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Vapotherm

2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

2.28 M 114 M 2.92 M - - - - 6.02 M 5.24 M - 5.36 M - - - 6.78 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

149 M 140 M 133 M 128 M 125 M 123 M 124 M 124 M 121 M 127 M 93.4 M 88.6 M 80.7 M 84 M 102 M 73 M 69.9 M 63.4 M 58.2 M 55.6 M 54.8 M 54.3 M 45.7 M 45.7 M 45.7 M 45.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

1.08 M 1.15 M 1.04 M 1.12 M 1.18 M 1.06 M 1.02 M 1.1 M 1.12 M 1.27 M 1.71 M 1.79 M 1.24 M 959 K 2.52 M 521 K 1.07 M 442 K 344 K 344 K 344 K 344 K 251 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-577 M -563 M -548 M -538 M -523 M -508 M -490 M -469 M -442 M -400 M -377 M -358 M -345 M -327 M -317 M -300 M -287 M -279 M -265 M -253 M -240 M -227 M -214 M -214 M -214 M -214 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

67.9 M 71.9 M 77.6 M 80.6 M 90.1 M 101 M 96.2 M 113 M 135 M 181 M 160 M 171 M 174 M 191 M 216 M 202 M 209 M 105 M 112 M 121 M 84.2 M 95.3 M 97.2 M 97.2 M 97.2 M 97.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

2.9 M 3.3 M 9.72 M 14.4 M 18 M 25.7 M 15.7 M 28.7 M 49.9 M 72.9 M 57.1 M 70.3 M 81.5 M 93.8 M 114 M 139 M 148 M 60.4 M 71.7 M 83.5 M 46.1 M 56.7 M 58.2 M 58.2 M 58.2 M 58.2 M 26.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

-81.3 M -68.5 M -55.3 M -47.5 M -34.5 M -22.4 M -28.2 M -10.9 M 13.7 M 53.9 M 66.7 M 82.2 M 93.2 M 107 M 114 M 129 M 139 M 41.4 M 53.7 M 65.1 M 29.3 M 41 M 51.6 M 51.6 M 51.6 M 51.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

-81.3 M -68.5 M -55.3 M -47.5 M -34.5 M -22.4 M -28.2 M -10.9 M 13.7 M 53.9 M 66.7 M 82.2 M 93.2 M 107 M 114 M 129 M 139 M 41.4 M 53.7 M 65.1 M 29.3 M 41 M 51.6 M 51.6 M 51.6 M 51.6 M -127 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Vapotherm, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Medical devices

Issuer Price % 24h Market Cap Country
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 57.08 3.84 % $ 8.66 B usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
- - $ 162 M franceFrance
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 15.55 0.18 % $ 440 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
$ 8.8 6.24 % $ 642 M israelIsrael
Electromed Electromed
ELMD
$ 29.6 0.27 % $ 245 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 0.71 0.69 % $ 12 M usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 80.32 0.36 % $ 4.38 B britainBritain
LENSAR LENSAR
LNSR
$ 8.3 0.24 % $ 99.3 M usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.34 0.15 % $ 21.2 M usaUSA
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
ThermoGenesis Holdings ThermoGenesis Holdings
THMO
- -25.84 % $ 171 K usaUSA
Talis Biomedical Corporation Talis Biomedical Corporation
TLIS
- 3.55 % $ 7.96 M usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Butterfly Network Butterfly Network
BFLY
$ 8.43 0.93 % $ 2.08 B usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Integer Holdings Corporation Integer Holdings Corporation
ITGR
$ 125.33 0.02 % $ 4.35 B usaUSA